Aptar's Profitability Improving Due to Pharma Growth and Cost Controls
Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...
Pharmaceutical Technology3h
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
Tiny water-based reactors could help pharmaceutical industry avoid toxic solvents
Researchers at Rice University have developed a new method for performing chemical reactions using water instead of toxic ...
Pharma making strides in AI use
The number of clinical trials in which AI designed or repurposed molecules, or targeted diseases, has more than doubled since ...
gulftoday8h
Qatar and Turkey join regional Integrated Industrial Partnership
The fifth meeting of the Higher Committee for Integrated Industrial Partnership for Sustainable Economic Development held in ...
Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Pharmaceutical Technology11h
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Supply Chain19h
U.S. Pharma Companies Weigh a Shift to North America — and Possibly the U.S. — for Drug Production
“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...